Femasys Inc (FEMY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Femasys Inc (FEMY) has a cash flow conversion efficiency ratio of -0.568x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.14 Million) by net assets ($7.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Femasys Inc to measure how many days the company can operate on defensive assets alone.
Femasys Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Femasys Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Femasys Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Femasys Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nukkleus Inc
NASDAQ:NUKK
|
0.033x |
|
FASING SA
WAR:FSG
|
0.009x |
|
Sahathai Terminal Public Company Limited
BK:PORT
|
0.050x |
|
NSN Co. Ltd
KQ:031860
|
-0.143x |
|
Cosmos Health Inc.
NASDAQ:COSM
|
-0.249x |
|
Barramundi Group Ltd
OL:BARRA
|
0.044x |
|
Sejoong Co. Ltd
KQ:039310
|
-0.005x |
|
Bodhi Tree Multimedia Limited
NSE:BTML
|
0.001x |
Annual Cash Flow Conversion Efficiency for Femasys Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Femasys Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see FEMY market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.87 Million | $-18.69 Million | -3.184x | +62.26% |
| 2024-12-31 | $2.30 Million | $-19.44 Million | -8.438x | -1272.75% |
| 2023-12-31 | $18.35 Million | $-11.28 Million | -0.615x | +12.70% |
| 2022-12-31 | $15.24 Million | $-10.73 Million | -0.704x | -133.77% |
| 2021-12-31 | $26.33 Million | $-7.93 Million | -0.301x | +78.46% |
| 2020-12-31 | $3.53 Million | $-4.93 Million | -1.398x | -676.44% |
| 2019-12-31 | $-45.37 Million | $-11.01 Million | 0.243x | -- |
About Femasys Inc
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal pat… Read more